secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001654954-24-005715
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata shareholders approve reverse stock split (1:5-1:30) and equity plan expansion
--------------------------------------------------------------------------------

- Stockholders approved reverse stock split at ratio from 1:5 to 1:30, exact ratio to be set by Board.
- Equity plan amended to increase share reserve from 629,069 to 1,198,951 and raise annual evergreen to 5%.
- Three Class III directors elected: Proehl, Wierenga, and Scott.
- Ratified Moss Adams LLP as auditor for FY2024.
- Adjournment proposal also approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424005715/0001654954-24-005715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424005715/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-005715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer